Bobby Bringi, CEO of MBI, inducted into The American Institute for Medical Biological Engineering’s College of Fellows
LANSING, Mich. — The American Institute for Medical and Biological Engineering (AIMBE) will induct Bobby Bringi, Ph.D., who is CEO of MBI (Michigan Biotechnology Institute), to its College of Fellows at a March 16 ceremony in Washington, D.C. The College of Fellows is comprised of the top 2 percent of medical and biological engineers in the country.
Dr. Bringi was elected by peers and members of the College of Fellows for “the development of plant cell fermentation process to make taxol and leadership of Michigan Biotechnology Institute.” MBI — a Lansing, Michigan-based not-for-profit biotech accelerator and a wholly owned subsidiary of the Michigan State University Foundation — is pioneering the AFEX technology platform, a game-changing solution to the world’s grand challenge of feeding 9 billion people by the year 2050.
Bringi has broad experience and expertise in biobased technology development. Prior to joining MBI in December 2006, Bringi and his team developed and successfully commercialized an innovative way to produce the anti-cancer drug Taxol, without having to cut down 100-year-old yew trees. This entrepreneurial experience allowed Bringi to conceive and champion derisking, MBI’s unique process that quickly and cost-effectively fails flawed technologies while accelerating viable ones through a rigorous innovation process. As a mission-inspired, market-driven 501(c)(3), MBI is demonstrating its multidisciplinary approach to innovation through a campaign seeking philanthropic partners for its AFEX platform. AFEX is a biobased technology that converts cellulose — the planet’s most ample organic material, found in plants and in the abundant crop residue left over from grain harvests — into a sustainable source of cattle feed and biofuels.
Bulky and unwieldy crop residues and grasses are converted into easily transported pellets, and since the conversion takes place in a decentralized system of depots built where crops are grown, the technology platform allows the world’s rural poor to earn more for their families. MBI’s vision is to make AFEX available worldwide on an affordable, accessible basis, maximizing the technology’s global and societal impact. 300 million tons of AFEX pellets could replace all grain currently fed to beef and dairy cattle, freeing up enough grains to feed 1 billion people. For more information on AFEX, go to mbi.org/afex.
The formal induction ceremony will be held March 16 during AIMBE’s 2015 Annual Meeting at the National Academy of Sciences Great Hall in Washington, D.C. Dr. Bringi will be inducted at that time along with 151 colleagues who make up the AIMBE College of Fellows Class of 2015.
The most accomplished and distinguished engineering and medical school chairs, research directors, professors, innovators, and successful entrepreneurs, comprise the College of Fellows. AIMBE Fellows are regularly recognized for their contributions in teaching, research, and innovation. AIMBE Fellows have been awarded the Presidential Medal of Science and the Presidential Medal of Technology and Innovation and many also are members of the National Academy of Engineering, Institute of Medicine, and the National Academy of Sciences.
About MBI, AIMBE, and Dr. Bringi
MBI (Michigan Biotechnology Institute) is both a premier multidisciplinary center sought out by industry partners for unique derisking capabilities—and a mission-inspired 501(c)(3) not-for-profit that collaboratively accelerates the commercialization of bio-based technologies. MBI is known for pioneering derisking, a process that quickly and cost-effectively fails flawed technologies while accelerating viable ones through a stage-gated innovation process. Lansing, Michigan-based MBI engages with universities, research institutions and corporations to develop sustainable fuels, chemicals, food and feed. Collaborators have included DuPont, Genomatica and Novozymes. MBI has also worked with Michigan State University and Cargill to develop PLA, the first biodegradable polymer in global use. Technologies developed at MBI are recognized and trusted worldwide. Learn more at mbi.org.
AIMBE’s mission is to recognize excellence in, and advocate for, the fields of medical and biological engineering in order to advance society. Since 1991, AIMBE‘s College of Fellows has lead the way for technological growth and advancement in the fields of medical and biological engineering. Fellows have helped revolutionize medicine and related fields in order to enhance and extend the lives of people all over the world. They have also successfully advocated for public policies that have enabled researchers and business-makers to further the interests of engineers, teachers, scientists, clinical practitioners, and ultimately, patients. For questions regarding the College of Fellows and AIMBE, please contact Milan P. Yager, AIMBE Executive Director at firstname.lastname@example.org, or call the AIMBE office at 202-496-9660.
Dr. Venkataraman [Bobby] Bringi is a biotechnology innovator and entrepreneur, currently serving as CEO of Lansing, Michigan-based MBI. Dr. Bringi is also a Visiting Adjunct Professor at the Michigan State University’s Department of Chemical Engineering and Materials Science. Prior to leading MBI, he co-founded and built Phyton, Inc., an enterprising venture that developed and commercialized a breakthrough sustainable route to the anti-cancer drug paclitaxel in collaboration with Bristol Myers Squibb. He earned his doctorate from Cornell University in chemical engineering (class of 1991), where he also studied plant cell biology and biochemical sciences. He earned his master of science in chemical engineering from Colorado State University (class of 1985), and his bachelor of technology in chemical engineering from the Indian Institute of Technology (Banaras Hindu University), Varanasi, India (class of 1983). A global citizen, Bringi relishes the notion of arte e scienza, and has a passion for composing and performing global roots music. He resides with his wife and son in Okemos, Michigan.